Prednitop cream 0.25% tube 10 g

Pharmacological properties

Pharmacodynamics. Prednicarbate - the active ingredient for external use, which is contained in the drug, is an improved potent glucocorticoid with a pronounced anti-inflammatory, anti-allergic, anti-exudative, anti-proliferative and antipruritic effect.

Pharmacokinetics: With topical application of the drug, systemic absorption is insignificant.

Indication

Inflammatory skin diseases requiring the use of topical corticosteroids.

Application

Prednitop cream - treatment of acute skin diseases (e.g. hyperemia, ulcers).

Prednitop ointment - treatment of wet or dry skin diseases.

Prednitop fatty ointment - treatment of chronic skin diseases (e.g. peeling, coarsening of skin folds). Apply topically.

The drug is applied once a day in a thin layer to the affected areas of the skin. If necessary, the frequency of application of the drug can be increased to 2 times a day.

The course of treatment is determined by the doctor, usually it is no more than 2 weeks.

Note: The tube has an original cap. Before first use, you must pierce a hole in the aluminum membrane using the rod of the original cap.

Cutaneous solution. The drug is intended for use on the scalp.

The drug is applied in a small amount once a day to the affected areas of the skin, but not more than 30% of the skin surface, rubbing in lightly.

The drug is available in bottles with a dropper for application directly to the affected areas of the skin. The course of treatment is determined by the doctor, usually the treatment lasts up to 3 weeks.

Contraindication

Hypersensitivity to prednicarbate or to any other component of the drug; the presence of a skin reaction to vaccination; bacterial skin symptoms (e.g. tuberculosis, syphilis), as well as skin symptoms of viral diseases (e.g. chickenpox or infectious manifestations of herpes simplex); perioral dermatitis, rosacea or acne rosacea.

Side effects

During treatment with Prednitop, undesirable side effects may occur - telangiectasia, skin redness and striae on the skin, rosacea-like dermatitis with or without skin thinning. Abrupt cessation of therapy may provoke deterioration of wound healing. Due to the immunosuppressive effect of GCS, latent or increased development of existing skin infections, skin discoloration, hypertrichosis may occur.

With prolonged use of the drug or its application to large areas of the skin, especially when applying airtight bandages, hormonal imbalance or the development of drug-induced Cushing's syndrome may occur as a result of the active substance entering the body.

Special instructions

Do not apply the drug to the areas around the eyes. If you did not apply the drug the previous time, do not double the dose. Continue treatment according to the doctor's instructions.

When applied to the skin around the eyes: regular contact of corticosteroids with the conjunctival sac may lead to increased intraocular pressure.

For bacterial and/or fungal skin infections: topical treatment of bacterial and/or fungal skin infections with Prednitop is possible only with drugs that have antibacterial or antifungal effects. Possible hypersensitivity to cetyl and stearyl alcohol should be taken into account.

Use during pregnancy and breastfeeding. During pregnancy, the drug can be used only if the benefit to the mother outweighs the potential risk to the fetus. Do not apply the drug to large areas of skin. The active substance - prednicarbate - penetrates into breast milk, so breastfeeding should be avoided during treatment.

Children. Prednitop should only be used in infants if the benefit outweighs the potential risk. Prednitop use in infants may cause Cushing's syndrome due to increased metabolism.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. No data.

Interactions

Not described.

Overdose

Short-term use of increased doses of the drug (too large an amount, too large an application area, or too frequent use) does not cause any side effects.

Storage conditions

At a temperature not exceeding 25 °C.